Perceptions, intentions, and actual use of a consumer nicotine gum.
Harm reduction
Nicotine gum
Perception and intention studies
Tobacco
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
13 09 2023
13 09 2023
Historique:
received:
29
03
2022
accepted:
30
08
2023
medline:
14
9
2023
pubmed:
13
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
Little is known about perceptions, use intentions, and behaviors of adults regarding nicotine gum that is marketed and regulated as a consumer product rather than as a medicinal nicotine replacement therapy (NRT). Survey data were collected from a Qualtrics online panel (N = 1000) of adults who had never used a consumer nicotine gum, recruited based on smoking behavior, and from current and former purchasers of one commercially available nicotine gum product (LUCY Chew and Park), recruited via emails to a customer database (N = 500). In addition to descriptive cross-sectional analyses, logistic regression was used to estimate the probability of intent to try and of product appeal among these different groups. Among online panel respondents, individuals who smoked with and without plans to quit showed high intention to try the product (odds ratios 15.6 [95% CI 9.3, 27.6] and 9.8 [95% CI 5.8, 17.3] respectively, compared to people who formerly smoked) and persons who had never smoked showed low intentions to try. These results stood regardless of flavor. Among current and former purchasers of the study product, 43.4% of persons who had smoked cigarettes regularly indicated they were motivated to try the product "to help me quit smoking." Only 0.6% of young adult consumers of the nicotine gum (aged 21-30) had not tried tobacco products previously. Consumer nicotine gum does not appear to attract those who have never used a tobacco product and the results for young adults suggest minimal appeal to youth. The study product was used primarily by individuals who currently smoke and/or use e-cigarettes but who wished to quit or reduce consumption. These results suggest that a consumer nicotine gum may reduce harm by substituting for higher-risk products such as combustible cigarettes.
Sections du résumé
BACKGROUND
Little is known about perceptions, use intentions, and behaviors of adults regarding nicotine gum that is marketed and regulated as a consumer product rather than as a medicinal nicotine replacement therapy (NRT).
METHODS
Survey data were collected from a Qualtrics online panel (N = 1000) of adults who had never used a consumer nicotine gum, recruited based on smoking behavior, and from current and former purchasers of one commercially available nicotine gum product (LUCY Chew and Park), recruited via emails to a customer database (N = 500). In addition to descriptive cross-sectional analyses, logistic regression was used to estimate the probability of intent to try and of product appeal among these different groups.
RESULTS
Among online panel respondents, individuals who smoked with and without plans to quit showed high intention to try the product (odds ratios 15.6 [95% CI 9.3, 27.6] and 9.8 [95% CI 5.8, 17.3] respectively, compared to people who formerly smoked) and persons who had never smoked showed low intentions to try. These results stood regardless of flavor. Among current and former purchasers of the study product, 43.4% of persons who had smoked cigarettes regularly indicated they were motivated to try the product "to help me quit smoking." Only 0.6% of young adult consumers of the nicotine gum (aged 21-30) had not tried tobacco products previously.
CONCLUSIONS
Consumer nicotine gum does not appear to attract those who have never used a tobacco product and the results for young adults suggest minimal appeal to youth. The study product was used primarily by individuals who currently smoke and/or use e-cigarettes but who wished to quit or reduce consumption. These results suggest that a consumer nicotine gum may reduce harm by substituting for higher-risk products such as combustible cigarettes.
Identifiants
pubmed: 37700314
doi: 10.1186/s12954-023-00864-0
pii: 10.1186/s12954-023-00864-0
pmc: PMC10498549
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Harm Reduct J. 2015 Jul 02;12:21
pubmed: 26135116
Addict Behav. 2010 Feb;35(2):147-51
pubmed: 19819640
Harm Reduct J. 2008 May 23;5:18
pubmed: 18500993
Harm Reduct J. 2012 Feb 29;9:10
pubmed: 22376006
J Subst Abuse Treat. 2020 May;112:36-41
pubmed: 32199544
Am J Prev Med. 2008 Feb;34(2):102-11
pubmed: 18201639
Harm Reduct J. 2022 Dec 1;19(1):131
pubmed: 36456941
Nicotine Tob Res. 2011 Jul;13(7):573-8
pubmed: 21454913
Addict Behav. 2018 Apr;79:219-225
pubmed: 29175027
Am J Public Health. 2016 Jul;106(7):1219-22
pubmed: 27077338
JAMA Pediatr. 2021 Aug 1;175(8):863-865
pubmed: 34028507
Harm Reduct J. 2021 Dec 4;18(1):123
pubmed: 34863207
Harm Reduct J. 2011 Jul 29;8:19
pubmed: 21801389
Prev Med. 2020 Nov;140:106099
pubmed: 32335031
Health Qual Life Outcomes. 2018 Sep 21;16(1):192
pubmed: 30241527
Nicotine Tob Res. 2022 Feb 14;24(3):333-341
pubmed: 34331447
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883
J Clin Pharmacol. 2023 Oct;63(10):1108-1118
pubmed: 37322571
PLoS One. 2017 May 25;12(5):e0178279
pubmed: 28542637
Nicotine Tob Res. 2022 Aug 6;24(9):1332-1343
pubmed: 35305014
Int J Health Sci (Qassim). 2016 Jul;10(3):425-35
pubmed: 27610066
Int J Environ Res Public Health. 2021 Jul 21;18(14):
pubmed: 34300168
Nicotine Tob Res. 2011 Feb;13(2):94-102
pubmed: 21147894
Addict Behav. 2023 May;140:107632
pubmed: 36731224
Drugs. 2013 Apr;73(5):407-26
pubmed: 23572407
Addiction. 2020 Nov;115(11):2123-2129
pubmed: 32285979
Nicotine Tob Res. 2010 Aug;12(8):817-22
pubmed: 20622023
J Behav Med. 2015 Apr;38(2):318-26
pubmed: 25348584
Cochrane Database Syst Rev. 2019 Apr 18;4:CD013308
pubmed: 30997928
Toxicol Rep. 2021 Jan 27;8:282-294
pubmed: 33552927
Subst Use Misuse. 2022;57(8):1328-1331
pubmed: 35586938
Prev Med. 2021 Sep;150:106567
pubmed: 33957153
Tob Control. 2017 Mar;26(e1):e49-e58
pubmed: 27625408
Addict Behav. 2018 Feb;77:7-15
pubmed: 28938110
Tob Induc Dis. 2010 Jul 13;8:8
pubmed: 20626883
MMWR Surveill Summ. 2019 Nov 06;68(12):1-22
pubmed: 31805035
Am J Prev Med. 2009 Feb;36(2):96-104.e1
pubmed: 19135903
Patient Relat Outcome Meas. 2011 Jul;2:111-7
pubmed: 22915971
Addiction. 2003 Dec;98(12):1747-53
pubmed: 14651507
Tob Control. 2020 Jan;29(Suppl 1):s50-s58
pubmed: 29432136
Am J Addict. 2020 Jul;29(4):279-286
pubmed: 32176374
Harm Reduct J. 2020 Sep 10;17(1):62
pubmed: 32912217
Tob Control. 2009 Aug;18(4):324-32
pubmed: 19240228